U.S. Physical Therapy, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US90337L1089
USD
76.30
0.89 (1.18%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About U.S. Physical Therapy, Inc. stock-summary
stock-summary
U.S. Physical Therapy, Inc.
Pharmaceuticals & Biotechnology
U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries. The Company's segment is made up of various clinics within partnerships. The Company primarily operates through subsidiary clinic partnerships, in which it owns a general partnership interest and a limited partnership interest, and the managing therapists of the clinics owns the remaining limited partnership interest in the clinics. The Company operates approximately 550 physical therapy clinics in 39 states. In addition to owning and operating clinics, the Company manages approximately 38 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups.
Company Coordinates stock-summary
Company Details
1300 W Sam Houston Pkwy N Ste 300 , HOUSTON TX : 77043-4011
stock-summary
Tel: 1 713 2977000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 66 Schemes (47.32%)

Foreign Institutions

Held by 84 Foreign Institutions (7.26%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Edward Kuntz
Independent Chairman of the Board
Mr. Christopher Reading
President, Chief Executive Officer, Director
Mr. Reginald Swanson
Director
Mr. Mark Brookner
Independent Director
Mr. Harry Chapman
Independent Director
Ms. Kathleen Gilmartin
Independent Director
Dr. Bernard Harris
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
197 Million
(Quarterly Results - Jun 2025)
Net Profit:
19 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,477 Million (Small Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

181.62%

stock-summary
Debt Equity

0.33

stock-summary
Return on Equity

10.24%

stock-summary
Price to Book

2.95